Related Experiment Videos
A difference in mortality between two strains of jaundiced rats
P E Stobie1, C T Hansen, J R Hailey
1Laboratory of Biochemistry, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.
Pediatrics
|January 1, 1991
Summary
New rat models for neonatal hyperbilirubinemia were developed. The RHA/N-j strain shows low mortality and no kernicterus, while ACI/N-j rats exhibit high mortality and kernicterus, offering distinct models for research.
Area of Science:
- Genetics
- Animal Models
- Biochemistry
Background:
- Homozygous Gunn rats, lacking bilirubin glucuronyltransferase, serve as a model for neonatal hyperbilirubinemia and kernicterus.
- The Gunn mutation (j) causes jaundice due to impaired bilirubin conjugation.
Purpose of the Study:
- To develop and characterize two new inbred rat strains carrying the Gunn mutation.
- To compare the phenotypes, mortality, and incidence of kernicterus in these new strains.
Main Methods:
- Breeding mutant Gunn gene (j) into RHA/N and ACI/N rat strains to create RHA/N-j and ACI/N-j lines.
- Liver assays to confirm absence of transferase activity.
- Monitoring mortality, kernicterus signs (ataxia), serum bilirubin, and albumin concentrations through 8 weeks of age.
Main Results:
- Both RHA/N-j and ACI/N-j strains confirmed absence of transferase activity.
- RHA/N-j rats showed low mortality (20%) comparable to non-jaundiced littermates.
- ACI/N-j rats exhibited significantly higher mortality (81% vs 34%) and frequent kernicterus (73% vs 11%) compared to RHA/N-j.
- Serum bilirubin and albumin levels were comparable, with a higher bilirubin-to-albumin ratio at 20 days in ACI/N-j rats.
Conclusions:
- The RHA/N-j rat strain provides a valuable model for neonatal hyperbilirubinemia with minimal mortality and no kernicterus.
- The ACI/N-j rat strain presents a model with high incidence of kernicterus and mortality, useful for studying severe hyperbilirubinemia.
- These distinct strains offer differential models for investigating the pathogenesis and treatment of hyperbilirubinemia.